Skip to main content
. 2019 May 10;104(11):2215–2224. doi: 10.3324/haematol.2018.205351

Figure 6.

Figure 6.

Schematic summarizing the effect of K-RasG12D on pre-leukemic hematopoietic stem cells (HSC). HSC that acquire Aml1-ETO gain a competitive advantage, leading to an expansion in HSC number. Acquisition of K-RasG12D and Aml1-ETO concurrently leads to HSC depletion. It remains to be determined whether sequential acquisition of Aml1-ETO followed-by K-RasG12D might support development of leukemia. As this was not tested in the current study, this is depicted as a dotted arrow.